Stanford Study Shows Americans Inhaling Unintended Substances

Jun.02.2022
Stanford Study Shows Americans Inhaling Unintended Substances
A new study from Stanford University reveals that Americans are vaping non-nicotine substances, which can harm the lungs.

According to a report by FUTURITY website, a new study conducted by Stanford University reveals that Americans are consuming substances they never thought of inhaling before, including melatonin, essential oils, tea, vitamins, caffeine, and other non-nicotine substances.

 

This survey questioned the usage habits of over 6,000 adolescents, young adults, and adults aged 13-40. It is the first nationwide sample survey on the intake of non-nicotine products.

 

Scientists say that while some non-nicotine substances may be safe for ingestion, inhaling them through vaporization may harm the lungs. Chemicals, solvents, and flavors found in non-nicotine vaping products also exist in nicotine vaping products and have been shown to have harmful effects unrelated to nicotine.

 

According to Bonnie Halpern-Felsher, a professor of pediatrics at Stanford University School of Medicine and a senior author of a paper on the online edition of the Journal of the American Medical Association, "Our most striking finding was that nearly 14% of youths and 24% of young adults had used non-nicotine electronic cigarettes.

 

Non-nicotine electronic cigarettes currently evade regulation by the Food and Drug Administration for nicotine e-cigarettes or intake supplements, which means there are no restrictions on the equipment, ingredients, or marketing of these products. Additionally, there is no age limit for purchasing these products. According to Halpern-Felsher, many sellers make unfounded health claims, making electronic cigarettes appear safe to both youth and adults, despite their safety never being tested.

 

According to Halpern-Felsher, "Anything that is purchased, heated, and inhaled without a prescription is harmful to your lungs.

 

Investigation reveals

 

Researchers surveyed teenagers, young adults, and adults living across the United States, focusing on four age groups: 13-17, 18-20, 21-24, and 25-40. These groups represent different stages of development: early adolescence, young adulthood below the legal age for nicotine e-cigarette sales, prefrontal brain maturation during young adulthood, and adulthood. Participants' gender, race, and ethnicity were representative of the US population.

 

Participants answered questions about their use of non-nicotine electronic cigarettes, nicotine-containing electronic cigarettes, and combustible cigarettes. The survey asked if participants had ever used these products, if they had used them recently, and the timing of their first use of each product. The survey also included questions about usage patterns, specific brands, preferred flavors, and ingredients used in non-nicotine vaping devices.

 

Overall, approximately 26% of participants reported trying non-nicotine e-cigarettes, with nearly 17% reporting use within the past 30 days and approximately 12% within the past 7 days. Usage varied according to age, with the 21-24 year old group reporting the highest proportion of non-nicotine use (approximately 38%), followed by the 25-40 year old group at nearly 33%.

 

Approximately 14% of 13 to 17-year-olds and 24% of 18 to 20-year-olds have reported trying non-nicotine electronic cigarettes, with more than half of those individuals using these devices multiple times. On average, participants reported trying non-nicotine e-cigarettes at a younger age than nicotine e-cigarettes, raising concerns that non-nicotine devices could be a pathway to using nicotine-containing products.

 

What substances are people inhaling?

 

Many young survey participants are unaware of what they are vaping. Approximately 24% of teenagers aged 13 to 17 and 19% of young adults aged 18 to 20 reported that they do not know what is in the non-nicotine e-cigarettes they use.

 

Popular substances for consumption among teenagers and young people include tetrahydrocannabinol (THC), an active compound found in marijuana. Other substances include melatonin, cannabidiol (CBD), a non-psychoactive derivative of marijuana, essential oils, caffeine, and tea.

 

Among adults aged 25-40, caffeine, vitamin B, tea, and tetrahydrocannabinol are all popular. A complete list of substances found in non-nicotine electronic cigarettes includes vitamin C, lavender, essential oils, propylene glycol, glycerin, and other flavorings.

 

Halpern-Felsher stated that while the use of marijuana compounds isn't surprising, the popularity of other substances is unexpected and concerning.

 

The Food and Drug Administration has designated certain chemicals added to food, including vitamins and some flavorings, as "generally recognized as safe." However, this is not always the case.

 

According to Halpern-Felsher, the designation of GRAS (an indicator used by the US FDA to evaluate safety of food additives) means that certain things are safe to consume or use as a skin cream. However, there is a significant difference when it comes to inhaling aerosols produced by heating substances. This is where it affects your lungs.

 

Halpern-Felsher emphasized that the safety and potential risks or side effects of inhaling these substances are still not clear. Furthermore, non-nicotine e-cigarettes share common ingredients with nicotine-containing e-cigarettes, such as propylene glycol, glycerin, and flavoring compounds, all of which are known to be harmful to the lungs.

 

Unknown dangers

 

Halpern-Felsher has stated that for several common substances that are smoked, our existing knowledge of their chemical properties indicates that they pose harm to the lungs, and consumers should remain cautious.

 

She said, 'We really need toxicologists and other scientists to help us understand the impact of these chemicals on our bodies and by what mechanisms.' For example, she noted that excessive amounts of vitamins can have toxic effects. Pulmonary surfactants are oily substances produced by the body to lubricate lung air sacs. Inhaling evaporated fatty substances, such as essential oils, glycerin (a common ingredient in all e-cigarettes), and aromatic compounds, may interfere with lung function.

 

The message for everyone, especially young people, is that any inhaled aerosol, except for medication prescribed by a doctor (such as asthma treatment), could potentially be dangerous.

 

Halpern-Felsher stated, "Maintaining the health of our lungs has never been as critical as it is now during the COVID-19 pandemic.

 

She hopes that these findings will stimulate policy changes to better regulate the electronic cigarette industry, especially in terms of protecting youth.

 

We cannot allow non-nicotine products to be available for purchase in the open market anymore, especially considering the fact that young people are sharing and inhaling them without knowing what substances they contain. We need regulation and labelling measures to ensure that these products do not end up in the hands of young people.

 

Source: FUTURITY.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
Ahead of the Formula 1 race in Madrid, 67 Spanish and international public-health, medical and consumer organizations have sent an open letter to F1 President and CEO Stefano Domenicali calling for an end to sponsorships linked to the tobacco and nicotine industry, including nicotine pouches, vaping products and heated tobacco. The letter focuses on Philip Morris International’s ZYN partnership with Ferrari and British American Tobacco’s long-running partnership with McLaren and exposure for VELO. The campaign follows a March letter in which more than 160 organizations worldwide made a similar request to Formula 1.
Sep.10
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
South Korean Lawmaker Jeong Jin-wook Pushes Synthetic Nicotine Vape Probe, Highlighting Supply Chain and Tax Concerns
South Korean Lawmaker Jeong Jin-wook Pushes Synthetic Nicotine Vape Probe, Highlighting Supply Chain and Tax Concerns
South Korean lawmaker Jeong Jin-wook has again called for stronger government action against liquid synthetic nicotine vape manufacturers and sellers, alleging that some businesses may have avoided regulation through product labeling changes and corporate restructuring. According to Newsworks, JNILBO and other Korean reports, Jeong has held his third press conference on the issue, calling for a government-wide investigation. The dispute involves whether synthetic nicotine products should fall under tobacco regulations, tax implications and supply-chain transparency. South Korean government agencies have previously said some estimates of potential tax losses cannot be verified due to limited sales data.
Jul.27
Indiana’s Foreign-Made Vape Ban Takes Effect, Forcing Brands and Retailers to Adjust Supply Chains
Indiana’s Foreign-Made Vape Ban Takes Effect, Forcing Brands and Retailers to Adjust Supply Chains
A new Indiana law restricting the sale of foreign-made vape products has taken effect, requiring retailers to adjust inventory and sourcing practices. According to The Sun, WDRB and other reports, some local vape shops are reviewing product origins and supplier information to comply with the new requirements. The measure represents a broader shift in U.S. vape regulation, with oversight expanding beyond product authorization and sales rules toward manufacturing origin and supply-chain management.
Jul.24
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28